Please assess the completion status of the following clinical trial:

Trial Title: Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admitted patients who meets the clinical definition for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)~* Known or suspected gram-positive infection.~Exclusion Criteria:~* Known or suspected gram-negative infections, anaerobic infections, or fungemia~* Known or suspected infections that are severe, life threatening or are not included in the ABSSSI Food and Drug Administration (FDA) guidance~* Injection drug users with a fever~* Severe neurological disorder leading to immobility or confined to a wheelchair~* Bilateral Lower extremity involvement of the suspected infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- New Critical Pathway (Type: ACTIVE_COMPARATOR): The New Critical Pathway under study is defined as (1) use of guideline-based patient identification criteria, and, for those who meet these criteria, (2) use of dalbavancin, administered as a single intravenous (IV) dose of 1500 mg over 30 minutes for the treatment of ABSSSI.
- Usual Care (Type: ACTIVE_COMPARATOR): Participants who receive Usual Care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.

Based on this trial design, predict the completion outcome and termination type (if applicable).